Metastatic carcinoid and islet cell tumours of the pancreas: a phase II trial of the efficacy of combination chemotherapy with 5-fluorouracil, doxorubicin and cisplatin.

Abstract

A phase II trial of chemotherapy in carcinoid and islet cell pancreatic tumours has been conducted with the FAP protocol: 5-fluorouracil 400 mg/m2 per day (5-FU) for 3 days, 50 mg/m2 doxorubicin on day 2, and 90 mg/m2 cisplatin on day 2, repeated every 4 weeks. 24 patients, 20 non-pretreated and 4 pretreated, were included. For non-pretreated patients we observed 1 complete response and 2 partial responses. The response rate was 15% (95% confidence interval 0-31%). No response was observed in the pretreated patients. The toxicity was mainly digestive and haematological with 7 patients experiencing vomiting grade 3 and 3 patients with leucopenia grade 3. We conclude that the FAP protocol is of poor efficiency in endocrine tumours.

• Authors: P Rougier, J Oliveira, M Ducreux, C Theodore, J Kac, J P Droz
• Journal: European journal of cancer (Oxford, England : 1990) (Eur J Cancer) Vol. 27 Issue 11 Pg. 1380-2 ( 1991) ISSN: 0959-8049 [Print] England
• PMID: 1660291 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Doxorubicin
• Cisplatin
• Fluorouracil

Topics

• Adenoma, Islet Cell (drug therapy, mortality)
• Adult
• Aged
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Carcinoid Tumor (drug therapy, mortality, secondary)
• Cisplatin (administration & dosage)
• Doxorubicin (administration & dosage)
• Drug Evaluation
• Female
• Fluorouracil (administration & dosage)
• Humans
• Lung Neoplasms (drug therapy)
• Male
• Middle Aged
• Pancreatic Neoplasms (drug therapy, mortality)
• Prognosis